IMPACT THERAP-B (07630) plans to repurchase up to HK$100 million of the company's H shares.
IMPACT THERAP-B (07630) announced that the board of directors has resolved to repurchase the company's H shares from time to time on the open market of The Stock Exchange of Hong Kong Limited, with an aggregate amount not exceeding HK$100 million (including transaction costs such as brokerage commissions and stamp duty), pursuant to the general mandate approved by and granted to the company's directors by the company's shareholders at the annual general meeting held on June 25, 2026.
IMPACT THERAP-B (07630) announced that the board of directors has resolved to repurchase the company's H shares from time to time on the public market of The Stock Exchange of Hong Kong Limited, pursuant to the general mandate approved by the company's shareholders and granted to the company's directors at the annual general meeting held on June 25, 2026, for an aggregate amount not exceeding HK$100 million (including transaction costs such as brokerage commissions and stamp duty).
Related Articles
CHINA CINDA (01359) completes redemption of offshore preference shares
GENFLEET-B(02595): Multiple innovative combination therapies of the oral pan-RAS inhibitor GFH276 have recently received clinical trial approval, with clinical studies being conducted in China or overseas for first-line and later-line treatment of major-indication tumor types.
"1+1" is not yet greater than 2: Skyworks Solutions, Inc. (SWKS.US) combined revenue down 7% quarter-over-quarter, US$500 million synergy target to take two and a half years
CHINA CINDA (01359) completes redemption of offshore preference shares
GENFLEET-B(02595): Multiple innovative combination therapies of the oral pan-RAS inhibitor GFH276 have recently received clinical trial approval, with clinical studies being conducted in China or overseas for first-line and later-line treatment of major-indication tumor types.
"1+1" is not yet greater than 2: Skyworks Solutions, Inc. (SWKS.US) combined revenue down 7% quarter-over-quarter, US$500 million synergy target to take two and a half years
